Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 42%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc. is well-positioned for future growth due to a notable increase in Chromium reaction volumes, indicating a robust market despite ongoing pricing pressures in the pharmaceutical sector. The company's consumables, which are projected to grow at an impressive rate of 5-19 times by platform by 2027, are outpacing instrument revenue growth, highlighting strong demand for its integrated solutions. Overall, the demand for 10x Genomics's advanced platforms, including the Chromium and Visium systems, reflects the increasing need for high-resolution biological analysis, supporting a favorable long-term outlook for the company's stock performance.

Bears say

10x Genomics has experienced a contraction in 2024, facing double-digit pricing pressure that has negatively impacted revenue, alongside flat to modestly lower volumes, with projected growth not anticipated to recover until 2027. Additionally, the company's recent Q4 results revealed an earnings per share miss, reporting -$0.40 compared to an expectation of -$0.30, coupled with a full-year revenue outlook that fell below market expectations. Since its peak stock prices in 2021, the company has seen a decline of over 90%, indicating that its market segments have not expanded as anticipated, contributing to a negative outlook for the stock.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 42% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Buy based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.